Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?

Cucciniello, Linda; Gerratana, Lorenzo; Mastro, Lucia Del; Puglisi, Fabio

doi:10.1016/j.ctrv.2022.102445

Cited by 15 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, resistance to cisplatin in intrahepatic cholangiocarcinoma promotes the degradation of CDKN1B mRNA via YTHDF2 in an m 6 A-dependent manner ( 78 ). Tamoxifen is a conventional chemotherapy drug for breast cancer ( 79 ). Breast cancer develops tamoxifen resistance due to an increased ROS production and p38 activation.…”

Section: Amentioning

confidence: 99%

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Pan,

Tong,

Ren

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle-aged males between the ages of 45 and 60 years, and is the highest cause of cancer-associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N 6 -methyladenosine (m 6 A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m 6 A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m 6 A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m 6 A methylation modification in PCa. It is considered that the treatment of PCa with micro-molecular drugs that target the epigenetics of the m 6 A regulator to correct abnormal m 6 A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.

show abstract

Section: Amentioning

confidence: 99%

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Pan,

Tong,

Ren

et al. 2024

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Endocrine therapy can be used for all patients affected by BC that express ERs and PRs—specifically, LumA, LumB and normal-like BC and as adjuvant and neoadjuvant in several types of BCs [ 42 , 43 ]. However, due to the well-known limits of this type of therapy, the search for new ER inhibitors is still ongoing [ 44 ].…”

Section: Breast Cancer Therapiesmentioning

confidence: 99%

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta

Ceramella

Baldino

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of cancer death among women worldwide. Globally, BC is the second most frequent cancer and first most frequent gynecological one, affecting women with a relatively low case-mortality rate. Surgery, radiotherapy, and chemotherapy are the main treatments for BC, even though the latter are often not aways successful because of the common side effects and the damage caused to healthy tissues and organs. Aggressive and metastatic BCs are difficult to treat, thus new studies are needed in order to find new therapies and strategies for managing these diseases. In this review, we intend to give an overview of studies in this field, presenting the data from the literature concerning the classification of BCs and the drugs used in therapy for the treatment of BCs, along with drugs in clinical studies.

show abstract

“…Furthermore, YTHDF2 increased CDKN1B mRNA degradation in an m 6 A-dependent manner, which promoted intrahepatic cholangiocarcinoma (ICC) progression and reduced sensitivity to cisplatin treatment [121]. m 6 A modifications also play an integral part in tamoxifen resistance, a classical chemotherapeutic agent in breast cancer treatment [122]. METTL3 promoted the translation of AK4 mRNA by increasing m 6 A levels and facilitated ROS production and activation of p38, ultimately resulting in tamoxifen resistance [123].…”

Section: Induced Specific Drug Resistancementioning

confidence: 99%

Biological and pharmacological roles of m6A modifications in cancer drug resistance

et al. 2022

View full text Add to dashboard Cite

Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure. As a reversible epigenetic modification, N6-methyladenosine (m6A) RNA modification was regarded to be the most common epigenetic RNA modification. RNA methyltransferases (writers), demethylases (erasers), and m6A-binding proteins (readers) are frequently disordered in several tumors, thus regulating the expression of oncoproteins, enhancing tumorigenesis, cancer proliferation, development, and metastasis. The review elucidated the underlying role of m6A in therapy resistance. Alteration of the m6A modification affected drug efficacy by restructuring multidrug efflux transporters, drug-metabolizing enzymes, and anticancer drug targets. Furthermore, the variation resulted in resistance by regulating DNA damage repair, downstream adaptive response (apoptosis, autophagy, and oncogenic bypass signaling), cell stemness, tumor immune microenvironment, and exosomal non-coding RNA. It is highlighted that several small molecules targeting m6A regulators have shown significant potential for overcoming drug resistance in different cancer categories. Further inhibitors and activators of RNA m6A-modified proteins are expected to provide novel anticancer drugs, delivering the therapeutic potential for addressing the challenge of resistance in clinical resistance.

show abstract

Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?

Cited by 15 publications

References 48 publications

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Targeting Breast Cancer: An Overlook on Current Strategies

Biological and pharmacological roles of m6A modifications in cancer drug resistance

Contact Info

Product

Resources

About

Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?

Cited by 15 publications

References 48 publications

Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Targeting Breast Cancer: An Overlook on Current Strategies

Biological and pharmacological roles of m6A modifications in cancer drug resistance

Contact Info

Product

Resources

About

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)

Role of N⁶‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review)